Back to today’s briefing

Story perspectives

AstraZeneca, BMS Dismiss $400B Merger Over Antitrust

8/7/2026

48 5 Full Breakdown

Summary

Story summary

Reuters reported on August 5, 2026 that AstraZeneca and Bristol Myers Squibb are not pursuing a merger.
The denial came after earlier reports that preliminary talks had hinted at a $400 billion deal.
AstraZeneca’s shares fell on Monday after the rumor but recovered after the denial, leaving the stock up 9 % in 12 months.
Analysts said antitrust hurdles and product overlap—BMS’s Opdivo versus AstraZeneca’s Imfinzi—make a merger unlikely.

History

Historical Context

In 1989 Beecham Group merged with SmithKline Beckman, forming SmithKline Beecham, which then combined with GlaxoWellcome in 2000 to create GlaxoSmithKline after intensive antitrust review in Europe and the United States. Regulators cite that precedent as AstraZeneca and Bristol Myers Squibb encounter comparable hurdles in their recent aborted merger discussions.

1 of 2

Story summary

Reuters reported on August 5, 2026 that AstraZeneca and Bristol Myers Squibb are not pursuing a merger.
The denial came after earlier reports that preliminary talks had hinted at a $400 billion deal.
AstraZeneca’s shares fell on Monday after the rumor but recovered after the denial, leaving the stock up 9 % in 12 months.
Analysts said antitrust hurdles and product overlap—BMS’s Opdivo versus AstraZeneca’s Imfinzi—make a merger unlikely.

1 / 2